Arexvy contains a recombinant RSV glycoprotein F antigen combined with GSK’s proprietary AS01E adjuvant.

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Following various phone and smartwatch apps (Fitbits, fitness trackers, etc.), people have been focusing on taking 10,000 ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in second-quarter profit, supported by continued strength in its HIV and oncology ...

Revenue in the second quarter of 2025 rose 1.3% to GBP7.99 billion from GBP7.88 billion, helping to push pretax profit up 26% to GBP1.89 billion from GBP1.50 billion. Core operating profit rose 12% at ...